Latest filings (excl ownership)
6-K
Current report (foreign)
30 Apr 24
6-K
Current report (foreign)
25 Apr 24
6-K
Current report (foreign)
19 Apr 24
6-K
Current report (foreign)
16 Apr 24
6-K
Alvotech Announces Increase in Number of Own Shares
22 Mar 24
20-F
2023 FY
Annual report (foreign)
20 Mar 24
6-K
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
20 Mar 24
6-K
Alvotech Appoints Interim Chief Quality Officer
1 Mar 24
6-K
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
26 Feb 24
6-K
Current report (foreign)
23 Feb 24
6-K
Current report (foreign)
15 Feb 24
6-K
Current report (foreign)
29 Jan 24
6-K
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
19 Jan 24
6-K
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
10 Jan 24
6-K
Current report (foreign)
3 Jan 24
6-K/A
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
30 Nov 23
6-K
Current report (foreign)
29 Nov 23
6-K
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
29 Nov 23
6-K
Alvotech Accepts Offer to Sell its Subsidiary in Hannover, Germany
15 Nov 23
6-K
Current report (foreign)
14 Nov 23
6-K
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
13 Nov 23
EFFECT
Notice of effectiveness
31 Oct 23
CORRESP
Correspondence with SEC
27 Oct 23
UPLOAD
Letter from SEC
26 Oct 23
F-3
Shelf registration (foreign)
20 Oct 23
6-K
Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04
12 Oct 23
6-K
Current report (foreign)
3 Oct 23
6-K
Current report (foreign)
25 Sep 23
6-K
Current report (foreign)
21 Sep 23
6-K/A
Current report (foreign) (amended)
7 Sep 23
6-K
Alvotech Announces Changes to the Leadership Team
5 Sep 23
6-K
Current report (foreign)
31 Aug 23
6-K
Alvotech Completes $100 Million
1 Aug 23
6-K
Provide Update on Strategic Biosimilars Partnership
24 Jul 23
424B3
Prospectus supplement
24 Jul 23
424B3
Prospectus supplement
24 Jul 23
EFFECT
Notice of effectiveness
24 Jul 23
EFFECT
Notice of effectiveness
21 Jul 23
CORRESP
Correspondence with SEC
20 Jul 23
UPLOAD
Letter from SEC
20 Jul 23
Latest ownership filings
SC 13G/A
Oaktree Acquisition Holdings II, L.P.
14 Feb 24
SC 13G
Oaktree Acquisition Holdings II, L.P.
14 Feb 23
SC 13D/A
Celtic Holdings SCA
18 Nov 22
SC 13D/A
Aztiq Pharma Partners S.a r.l.
18 Jul 22
SC 13D/A
Celtic Holdings SCA
15 Jul 22
SC 13D
Aztiq Pharma Partners S.a r.l.
5 Jul 22
SC 13D
Celtic Holdings SCA
27 Jun 22
SC 13G
YA II PN, Ltd.
22 Jun 22